Chimeric antigen receptor (CAR) T-cell therapy is one of the fastest-growing sectors within oncology therapeutic development. This advanced form of immunotherapy can deliver “designer” T-cells to specifically recognize, and attack, cancer based on unique tumor-associated antigens, offering a highly targeted and personalized approach. Recently, adoptive cell therapy (ACT) has received considerable attention due to the success of CAR T-cell therapy in treating hematological malignancies. This article focuses on CAR T-cell therapies in cancer and discusses how biopharmaceutical companies can leverage a comprehensive biomarker strategy for their drug development programs to accelerate clinical trial timelines and better predict clinical outcomes.

• Download